NM-RHLCCC-cobranding-horizontal.png

About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University

The cancer center was first established at Northwestern University in 1974. In 1991 the center was dedicated as the Robert H. Lurie Cancer Center of Northwestern University through a gift of endowment from Ann and Robert H. Lurie. The center's title was modified in 1997, when it was awarded the National Cancer Institute’s (NCI) highly competitive "comprehensive" designation — reflecting the Lurie Cancer Center’s dedication to the highest standards of cancer research, patient care, education, and community outreach.

 Today, the Lurie Cancer Center is one of only 47 NCI-designated Comprehensive Cancer Centers in the nation. In addition, the Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 27 of the world's leading cancer centers dedicated to quality, effectiveness, and efficiency of cancer care so that patients can live better lives and part of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities.

 The Lurie Cancer Center is affiliated with four teaching hospitals in Chicago — Northwestern Memorial Hospital, Ann & Robert H. Lurie Children's Hospital of Chicago , the Rehabilitation Institute of Chicago, and the Jesse Brown Veteran's Affairs Medical Center, treating more than 10,000 new cancer cases each year.

In the United States, approximately one in eight women will be diagnosed with breast cancer during her lifetime.  It is the most common cancer occurring in women (excluding skin cancer) and the second most common cause of death from cancer in women, after lung cancer. The Lurie Cancer Center is home to several faculty who are leading experts in the field of breast cancer, including William J. Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology and Deputy Director of the Lurie Cancer Center. Dr. Gradishar and his collaborators aim to develop and coordinate clinical trials designed to assess the efficacy of novel adjuvant therapies and therapeutic approaches for locally advanced and metastatic breast cancer. Philanthropic support helps the breast oncology program to 1) initiate clinical trials involving new agents for the treatment of advanced and early stage breast cancer; and 2) develop collaborative efforts between breast cancer laboratory investigators and clinical investigators. Our research efforts have been made possible thanks to the generous support of individuals like you. Your philanthropic gift will continue this novel research, supporting efforts to improve breast cancer therapies and, ultimately, saving lives.